Press Releases

and/or
567 News Releases found
Jedd Wolchok
Combination of Drugs Produces Dramatic Tumor Responses in Advanced Melanoma Patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published in <em>The New England Journal of Medicine</em> and presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
Richard Carvajal
New Therapy Shown To Improve Progression-Free Survival and Shrink Tumors in Rare Cancer for the First Time

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.
Ross Levine
Foundation Medicine and Memorial Sloan Kettering Cancer Center Announce Partnership to Advance Patient Care in Hematologic Cancers

Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.
Large Genomic Study Identifies Endometrial Cancer Subtypes, Treatment Opportunities

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.
The ESK1 monoclonal antibody was engineered to recognize WT1 peptides brought to the surface of cancer cells.
New Monoclonal Antibody Developed That Can Target Proteins Inside Cancer Cells

Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.
Memorial Sloan Kettering Appoints Avice Meehan as Vice President of Communications and Chief Communications Officer

In this new expanded role, Avice Meehan will streamline communications across the Center and lead both Memorial Sloan Kettering’s Public Affairs and Marketing endeavors.
Memorial Sloan Kettering Announces New Appointments

Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.
Drug Shown to Reverse Radioiodine Resistance in Some Advanced Thyroid Cancers

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.
Westchester Medical Center Opens New Outpatient Oncology Center in Partnership with Memorial Sloan Kettering

Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.
IBM Watson Hard At Work: New Breakthroughs Transform Quality Care for Patients

IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.